Detailed overview on rare malignant ovarian tumors

Aust, Stefanie; Eberst, Lauriane; Trédan, Olivier; Rousset‐Jablonski, Christine; Treilleux, Isabelle; Méeus, Pierre; Chopin, Nicolás; Beurrier, F.; Charreton, Amandine; Véronique, Daval; Hallouz, Amina; Coulon, A.; Ricoeur, Alexis; Mastier, Charles; Bouhamama, Amine; Racadot, S.; Devouassoux‐Shisheboran, Mojgan; Haddad, Véronique

doi:10.1016/j.bulcan.2020.01.011

Cited by 12 publications

(20 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An ovarian sarcoma is a type of nonspecific stromal cell tumor, including a pure ovarian sarcoma and malignant mixed Mullerian tumors (MMMTs) 5–7 . Pure ovarian sarcoma includes ovarian leiomyosarcoma, fibrosarcoma, and angiosarcoma, etc 1,5,6 . MMMTs can be divided into homologous and heterologous components according to differences in tissue composition 5,7 .…”

Section: Discussionmentioning

confidence: 99%

“…The pathogenesis of POLMS has not been established, but several common classifications are as follows. POLMS is derived from smooth muscle of ovarian interstitial blood vessels, 3 the smooth muscle fibers of the ovary or its anterior mesenchymal tissue, 6 the smooth muscle where the ovarian ligament attaches to the end of the ovary, 6 or the mesonephric duct remnants, which rarely forms neoplasms 9 . Other derivations are from the ectopic endometrial stroma of the ovary, 6 or the multipotential mesenchymal tissue in teratomas 3 .…”

Section: Discussionmentioning

confidence: 99%

“…POLMS is derived from smooth muscle of ovarian interstitial blood vessels, 3 the smooth muscle fibers of the ovary or its anterior mesenchymal tissue, 6 the smooth muscle where the ovarian ligament attaches to the end of the ovary, 6 or the mesonephric duct remnants, which rarely forms neoplasms 9 . Other derivations are from the ectopic endometrial stroma of the ovary, 6 or the multipotential mesenchymal tissue in teratomas 3 . In the above case, the morphology of the ovary was still partly visible during the operation, and the root of the tumor was very close to the blood supply artery of the ovary, thus, the POLMS in this case might derive from smooth muscle of ovarian interstitial blood vessels.…”

Section: Discussionmentioning

confidence: 99%

“…POLMS mostly occurs in postmenopausal women between 45 and 60 years of age, with a mean age of 54.3 ± 10.3 years 3,6,10 . The main symptoms include lower abdominal distension, abdominal pain, abdominal masses, changes in urination and defecation, and may be accompanied by weight loss and anemia 2,6 .…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Recurrent primary ovarian leiomyosarcoma preconception, pregnancy, delivery, and puerperal management: A case report and literature review

Fan

Wang

et al. 2022

J of Obstet and Gynaecol

View full text Add to dashboard Cite

A primary ovarian leiomyosarcoma (POLMS) is a rare malignant tumor of the ovary. Herein, we report a patient with an early‐stage POLMS who underwent unilateral adnexectomy in our department with a subsequent pregnancy, delivery, and tumor recurrence. In this case, the patient was a 29‐year‐old female with a complaint of abdominal distention who underwent a right adnexectomy for a solid tumor in the right ovary. The pathological diagnosis was a stage IA leiomyosarcoma of the right ovary. One month later, a recurrence in the left ovary tumor was diagnosed. The patient did not agree to further treatment. She subsequently achieved a spontaneous pregnancy and had an uneventful pregnancy and delivery at term. During the puerperium, she underwent radical surgery and chemotherapy with the recommended follow‐up evaluation. The literature review shows the pathogenesis of POLMS has not been established. There are no specific tumor markers, and it is difficult to distinguish the nature and origin of the tumor with imaging modalities, thus, early diagnosis is difficult. The malignancy rate is high, and the prognosis of advanced tumors is poor. To properly counsel patients to optimize treatment, more reports of cases, the disease course, treatments, and outcomes are needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Recurrent primary ovarian leiomyosarcoma preconception, pregnancy, delivery, and puerperal management: A case report and literature review

Fan

Wang

et al. 2022

J of Obstet and Gynaecol

View full text Add to dashboard Cite

show abstract

“…They are different from EOCs because they tend to be diagnosed in younger women, and due to their rapid tumor growth, they are usually symptomatic, thus leading to earlier diagnosis and a significantly better prognosis. Germ-cell tumors also have a different set of biomarkers such as alpha-fetoprotein (AFP), serum human chorionic gonadotropin (HCG), and lactate dehydrogenase (LDH) [42]. The most common mutations were found in KIT and KRAS, akin to testicular germ cell tumors [34].…”

Section: Common Versus Rare Ovarian Cancersmentioning

confidence: 99%

(In)Distinctive Role of Long Non-Coding RNAs in Common and Rare Ovarian Cancers

Sabol

Calleja‐Agius

Fiore

et al. 2021

Cancers

View full text Add to dashboard Cite

Rare ovarian cancers (ROCs) are OCs with an annual incidence of fewer than 6 cases per 100,000 women. They affect women of all ages, but due to their low incidence and the potential clinical inexperience in management, there can be a delay in diagnosis, leading to a poor prognosis. The underlying causes for these tumors are varied, but generally, the tumors arise due to alterations in gene/protein expression in cellular processes that regulate normal proliferation and its checkpoints. Dysregulation of the cellular processes that lead to cancer includes gene mutations, epimutations, non-coding RNA (ncRNA) regulation, posttranscriptional and posttranslational modifications. Long non-coding RNA (lncRNA) are defined as transcribed RNA molecules, more than 200 nucleotides in length which are not translated into proteins. They regulate gene expression through several mechanisms and therefore add another level of complexity to the regulatory mechanisms affecting tumor development. Since few studies have been performed on ROCs, in this review we summarize the mechanisms of action of lncRNA in OC, with an emphasis on ROCs.

show abstract

Anti‐oncogenic PTEN induces ovarian cancer cell senescence by targeting P21

et al. 2021

Cell Biology International

View full text Add to dashboard Cite

Deletion and mutation of phosphatase and tensin homolog deleted on chromosome10 (PTEN) are closely associated with the occurrence of tumors. Tumor suppressor gene PTEN mutation plays an important role in the pathogenesis of ovarian cancer. However, it has been unclear whether it can regulate the senescence of ovarian cancer cells. We speculated that PTEN might inhibit the occurrence and development of ovarian cancer by promoting the expression of P21. We found that the expression of TRIM39 in human ovarian cancer was significantly diminished. In SKOV3 cells treated with naringin, the expression of TRIM39, which binds P21 and inhibits P21 degradation, was significantly elevated. Real‐time polymerase chain reaction (PCR), Western blot, and immunofluorescence were used to detected the expression of PTEN, p21, and TRIM39, β‐galactosidase Staining was used to detect cell senescence, Ki67 staining was used to observe cell proliferation, Trim39 interference or overexpression assay was used to detect its function. We speculated that PTEN might promote SKOV3 cell senescence by increasing TRIM39 expression and decreasing P21 degradation. Furthermore, by interfering with TRIM39 in SKOV3 cells, we found that the expression of P21 was downregulated, and the number of senescent SKOV3 cells decreased. With overexpression of TRIM39 in SKOV3 cells, the expression of P21 was upregulated, and the number of senescent SKOV3 cells increased. When naringin, a PTEN agonist, was added to SKOV3 cells in which TRIM39 protein was interfered with, the expression of P21 was significantly lower than that in the control group, and the number of senescent ovarian cancer cells was significantly diminished. Our results indicated that PTEN maintained the stability of P21 and decreased the degradation of P21 by increasing TRIM39 expression, thus promoting the senescence of SKOV3 cells, and PTEN maintained the stability of p21 and promoted the aging of SKOV3 cells might be a novel therapeutic target for ovarian cancer.

show abstract

Detailed overview on rare malignant ovarian tumors

Cited by 12 publications

References 33 publications

Recurrent primary ovarian leiomyosarcoma preconception, pregnancy, delivery, and puerperal management: A case report and literature review

Recurrent primary ovarian leiomyosarcoma preconception, pregnancy, delivery, and puerperal management: A case report and literature review

(In)Distinctive Role of Long Non-Coding RNAs in Common and Rare Ovarian Cancers

Anti‐oncogenic PTEN induces ovarian cancer cell senescence by targeting P21

Contact Info

Product

Resources

About